Fabtech Technologies Ltd. rallied nearly 10 percent on June 16 after announcing a new overseas order worth Rs 31.23 crore.
The stock was trading around Rs 161 and touched an intraday high of Rs 165 following the announcement.
According to a regulatory filing dated June 15, 2026, the company has secured a contract for the internal infrastructure of a Veterinary Vaccine Manufacturing Facility in Botswana.
Scope of the project
Under the contract, Fabtech will provide:
- GMP-compliant internal infrastructure
- Advanced HVAC systems
- Clean utilities
- Mechanical, electrical and plumbing (MEP) services
The facility is designed to support large-scale veterinary vaccine production and strengthen healthcare manufacturing capacity in Southern Africa.
Africa expansion gathers pace
The order comes as African countries increase investments in local vaccine manufacturing.
The push gained momentum after supply chain disruptions witnessed during the COVID-19 pandemic.
The African Union has set a target of producing 60 percent of the continent’s vaccine requirements locally by 2040, creating opportunities for companies involved in pharmaceutical infrastructure.
The Botswana project adds another reference for Fabtech in the region and could help the company secure larger assignments in pharmaceutical and vaccine manufacturing facilities.
Order book reaches Rs 1,440 crore
The latest contract has further strengthened Fabtech’s order pipeline.
As of June 2026, the company had an unexecuted order book of Rs 1,440 crore, providing revenue visibility for nearly two years.
The Botswana project is the company’s fourth major African contract in the last 12 months.
Earlier projects were executed in:
- Egypt
- Kenya
The orders reflect the company’s focus on expanding its international business.
FY26 performance
Fabtech reported strong growth during FY26.
Key financial highlights:
- Revenue increased 38 percent year-on-year to Rs 842 crore.
- Net profit rose 52 percent to Rs 78 crore.
- International business contributed nearly 62 percent of total revenue.
The share of overseas business has increased from 45 percent two years ago, underlining the growing importance of international markets for the company.
With a market capitalisation of around Rs 715 crore, the stock is currently trading within its 52-week range of Rs 126 to Rs 263.
About the company
Fabtech Technologies Ltd. provides turnkey infrastructure solutions for the life sciences industry.
Its services include:
- Plant design
- Cleanroom engineering
- Advanced HVAC systems
- GMP-compliant manufacturing facilities
The company caters to pharmaceutical, biotechnology and healthcare clients across global markets.
TL;DR:
Fabtech Technologies shares gained nearly 10% after the company secured a Rs 31.23 crore contract for a veterinary vaccine manufacturing facility in Botswana. The order lifted its unexecuted order book to Rs 1,440 crore.
AI Summary:
- Fabtech won a Rs 31.23 crore contract in Botswana.
- The project involves infrastructure for a veterinary vaccine facility.
- The company’s order book stood at Rs 1,440 crore in June 2026.
- This is its fourth major African contract in the past year.
- FY26 revenue and profit rose 38% and 52%, respectively.
